The Cabinet of Ministers has announced a new regulation to address concerns regarding the concentration of power within the pharmaceutical industry. The measure prohibits the supply of a single drug to one distributor in amounts exceeding 20% of the total net income from these medicines’ sales in the previous year. This policy is intended to promote competition and prevent any single entity from gaining excessive control over critical medications.
Industry analysts speculate that this decision may have significant implications for the distribution networks of pharmaceutical companies. By limiting the volume of drugs that can be supplied to a single distributor, the government seeks to ensure that multiple players remain active in the market, thereby protecting consumers from potential price hikes or supply shortages. The policy also aims to safeguard the interests of smaller distributors who might otherwise be outcompeted by larger players.
The move has sparked a range of reactions from stakeholders within the healthcare sector. While some pharmaceutical companies have expressed concerns about the potential impact on their supply chains and profitability, others view the regulation as a necessary step to ensure fair market practices and prevent monopolistic behavior. As the government implements this new rule, it will be crucial to monitor its effects on both the industry and the availability of essential medications for patients.